Efficacy of ImmunoSEB™ in Treating Bacterial Infection and Its Role as a Bio-Enhancer with Antibiotics
Year: 2026
Type: article
Abstract: Bacterial infections pose a serious therapeutic challenge, particularly in the context of rising antibiotic resistance. ImmunoSEB™, a systemic enzyme blend, has been proposed as a combination therapy to enhance host immune response and improve antibiotic efficacy. 80-Swiss albino mice were randomized into 4-groups (n = 20 each): Infected control, Ampicillin (250 mg/kg/day), ImmunoSEB™ (400 mg/kg/day, administered 14-days prior and post-infection), and ImmunoSEB™ + Ampicillin combination. Infection was induced with E. coli ATCC25922. Thigh swelling was monitored daily, and bacterial load was quantified for 5-days post-treatment. Control mice exhibited marked thigh enlargement (90.77%) and high bacterial load (96.17 ± 24.24 CFU/g). Antibiotic (ampicillin) monotherapy slightly reduced the infection, with thigh swelling increasing to 103.92% and bacterial load remaining high (100.42 ± 34.45 CFU/g, non-significant over control). ImmunoSEB™ alone reduced thigh swelling to 100% and significantly lowered bacterial load to 70.58 ± 27.28 CFU/g (p<0.05). The combination therapy produced most prominent results, thigh swelling decreased to 75.73%, and bacterial load was nearly eradicated (2.25 ± 1.17 CFU/g, p < 0.001), representing a significant reduction compared to control. ImmunoSEB™-Ampicillin combination displayed near complete bacterial clearance and substantial inflammation resolution, highlighting its potential as an effective adjunct to conventional antibiotics in resistant bacterial infections. While these results in a murine model are encouraging, further studies are warranted to validate the findings.
Authors: Abhijit Rathi, V.L. Rathi
Institution: Advanced Enzyme Technologies Limited (India)
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7203444553